These patented compounds collectively highlight a growing trend in ATR, ATM and DNA-PK targeted cancer therapies, with increasing emphasis on combination approaches, improved drug delivery methods, and multi-targeted kinase inhibition to enhance treatment efficacy and overcome resistance mechanisms.291–302. This evidence concerns the gene ATR and cancer.